---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-001172"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T21:42:23.375260+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma signs exclusive worldwide license with U. Arizona for PLpro COVID-19 treatment

## Summary
- License grants exclusive worldwide rights to PLpro protease inhibitors of SARS-CoV-2 (COVID-19).
- Company pays 3% royalty on net sales and 30% of sublicensee revenues.
- Milestone payments required; University can terminate if milestones not met.
- Collaboration began February 2022; option to license was exercised.

## SEC filing metadata
- accession: 0001683168-23-001172
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316823001172/0001683168-23-001172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316823001172/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-001172
- JSON: https://secwatch.observer/filing/0001683168-23-001172.json
- Plain text: https://secwatch.observer/filing/0001683168-23-001172.txt

## Key facts
- Material Agreements
  Sunshine Biopharma Inc. entered into Exclusive Patent License Agreement with Arizona Board of Regents on behalf of the University of Arizona (effective 2023-02-24).
  - Action: entry
  - Agreement: license
  - Counterparty: Arizona Board of Regents on behalf of the University of Arizona
  - Effective: 2023-02-24
  source text: On February 24, 2023, Sunshine Biopharma, Inc. (the “Company”) entered into an Exclusive Patent License Agreement (the “License Agreement”) with Arizona Board of Regents on behalf of the University of Arizona (the “University”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316823001172/0001683168-23-001172-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.